# GLP-1 Maintenance and “Microdosing”: What the Labels Establish

Maintaining weight loss is a treatment goal. “Microdosing” does not identify an FDA-approved regimen or guarantee fewer side effects.

Canonical: https://velri.co/blog/microdosing-glp1-maintenance-weight-provider-monitoring
Publisher: Velri (https://velri.co/about)
Published: 2026-06-14
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

Maintaining weight loss is an established treatment goal for approved semaglutide and tirzepatide products. “Microdosing” is not an FDA-approved regimen described in their prescribing information.[1][2]

The term does not specify a standardized amount, schedule, or evidence-based maintenance plan.

## Starting and maintenance doses have different roles

Approved prescribing information distinguishes treatment initiation, dose escalation, and maintenance. The appropriate plan considers the product, indication, response, and tolerability.[1][2]

A small starting amount should not automatically be interpreted as an effective long-term maintenance regimen. A social-media schedule also cannot establish how someone should change an existing prescription.

## Maintaining a result still requires review

A plateau after weight loss may represent maintenance rather than loss of all treatment benefit. The review considers the full treatment course, appetite, side effects, nutrition, and relevant health conditions.

Weight-management medication may be used long term when beneficial and appropriate. NIDDK notes that weight regain can occur after stopping treatment.[3] That does not predict every individual's experience, but it makes an ongoing plan important.

## Lower does not automatically mean safer

Side effects and suitability depend on more than a dose label. Approved products have specific warnings, contraindications, and instructions.[1][2]

Compounded preparations add a separate issue: they are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before marketing.[4] Calling a preparation a microdose does not remove that distinction.

## Make the proposal specific

A maintenance discussion should identify the exact medication and preparation, the intended goal, what will be monitored, and when the plan will be reassessed.

If a service uses the word microdosing, the prescriber needs to explain the actual proposed regimen and the evidence behind it.

## Sources
[1] DailyMed - WEGOVY- semaglutide injection, solution
WEGOVY- semaglutide tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
[2] DailyMed - ZEPBOUND- tirzepatide injection, solution
ZEPBOUND- tirzepatide injection, solution
ZEPBOUND KWIKPEN- tirzepatide injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
[3] Prescription Medications to Treat Overweight & Obesity - NIDDK. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
[4] Compounding and the FDA: Questions and Answers | FDA. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support